Contraception and gynaecological care

被引：3

作者：

Cameron, Sharon ^{[1
,2
]}

机构：

[1] Dean Terrace Ctr, Family Planning & Well Women Serv, Edinburgh EH4 1NL, Midlothian, Scotland

[2] Royal Infirm, Edinburgh EH16 5SU, Midlothian, Scotland

来源：

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY | 2009年 / 23卷 / 02期

关键词：

oral contraceptive pill; intra-uterine system; hormonal contraception; non-contraceptive benefits; gynaecology; FUNCTIONAL OVARIAN CYSTS; DEPOT MEDROXYPROGESTERONE ACETATE; ADMINISTERED PROGESTOGEN LEVONORGESTREL; INTRAUTERINE SYSTEM; ORAL-CONTRACEPTIVES; LEUPROLIDE ACETATE; RANDOMIZED-TRIAL; CANCER-RISK; PELVIC PAIN; ENDOMETRIOSIS;

D O I：

10.1016/j.bpobgyn.2008.11.003

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Hormonal contraception, through suppression of ovarian activity or endometrial proliferation, can be used to treat and prevent a range of gynaecological disorders. There is evidence to Support the effectiveness of the levonorgestrel intra-Uterine system (LNG-IUS), combined oral contraceptive pill (COC) and progestogen-only injectable depot-medroxyprogesterone acetate for treating heavy menstrual bleeding and dysmenorrhoea. COCs are also an effective treatment for acne and hirsuitism, and may lessen the symptoms of premenstrual syndrome. There is good evidence that COCs can significantly reduce the risk of both ovarian and endometrial cancer. There is also some evidence that CM may prevent ovarian cysts, endometrial hyperplasia and fibroids. The LNG-IUS may be used as endometrial protection in women using hormone replacement therapy or tamoxifen. This chapter will deal with the evidence for both treatment and prevention of a range of gynaecological disorders of different hormonal contraceptive methods. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：211 / 220

页数：10

共 67 条

[1]

ABBOUSETTA AM, 2006, COCHRANE DB SYST REV, V4

[2] Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET? [J].

Al-Mizyen, E ;

Sabatini, L ;

Lower, AM ;

Wilson, CMY ;

Al-Shawaf, T ;

Grudzinskas, JG .

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2000, 17 (03) :140-146

[3]

[Anonymous], 2010, Medical eligibility criteria for contraceptive use, V4th

[4] Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results [J].

Archer, David F. ;

Jensen, Jeffrey T. ;

Johnson, Julia V. ;

Borisute, Hannah ;

Grubb, Gary S. ;

Constantine, Ginger D. .

CONTRACEPTION, 2006, 74 (06) :439-445

[5]

AROWOJOLU AO, 2007, COCHRANE DB SYST REV, V24

[6] Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea [J].

Bahamondes, Luis ;

Petta, Carlos A. ;

Fernandes, Arlete ;

Monteiro, Ilza .

CONTRACEPTION, 2007, 75 (06) :S134-S139

[7] Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism [J].

Batukan, Cem ;

Muderris, Iptisam Ipek ;

Ozcelik, Bulent ;

Ozturk, Ahmet .

GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (01) :38-44

[8]

Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1

[9] Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women [J].

Beral, V ;

Reeves, G ;

Banks, E .

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2005, 112 (06) :692-695

[10] Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates [J].

Biljan, MM ;

Mahutte, NG ;

Dean, N ;

Hemmings, R ;

Bissonnette, F ;

Tan, SL .

FERTILITY AND STERILITY, 1998, 70 (06) :1063-1069

← 1 2 3 4 5 6 7 →